Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (n=27), none of the patients had a mycological evidence for fungal infection, but 19% (5/27) developed liver test abnormalities without leading to isavuconazole discontinuation. Isavuconazole could be considered as an off-label empirical therapy only if patients cannot receive caspofungin or liposomal amphotericin B.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pharma.2024.10.005 | DOI Listing |
Publication Analysis
Top Keywords
off-label empirical
12
empirical treatment
8
invasive fungal
8
fungal infections
8
empirical therapy
8
isavuconazole
6
isavuconazole off-label
4
empirical
4
treatment invasive
4
infections good
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!